Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED Corporation (NYSE: CNMD) announced a private offering of $600 million in convertible senior notes due 2027. The offering may increase by an additional $100 million if the initial purchasers exercise their option. Proceeds are intended for costs related to the convertible note hedge transactions, repurchasing existing notes, and funding the acquisition of In2Bones Global, Inc. The notes will mature on June 15, 2027, and are subject to specific conversion conditions. The overall offering structure aims to minimize dilution of common stock upon conversion.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, payable on July 5, 2022, to shareholders of record as of June 15, 2022. The company specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties including orthopedics and general surgery. This dividend declaration reflects the company's commitment to return value to its shareholders amidst ongoing market uncertainties, including challenges posed by the COVID-19 pandemic.
CONMED Corporation (NYSE: CNMD) has announced a definitive agreement to acquire In2Bones Global, Inc. for $145 million upfront and up to $110 million in earnout payments over four years. The acquisition, aimed at expanding CONMED's orthopedic portfolio into the extremities market, is expected to close in late Q2 or early Q3 2022, pending regulatory approval. In2Bones reported 2021 revenues of $36.8 million with 80% gross margins. The deal is projected to contribute $20 million to CONMED's revenue in H2 2022 and to be accretive to adjusted EBITDA thereafter.
CONMED Corporation (NYSE: CNMD) reported financial results for Q1 2022, with sales reaching $242.3 million, marking a 4.1% increase year over year. Domestic revenue rose 5.9%, while international revenue grew 2.2%. Diluted EPS was $0.47, up 51.6% from Q1 2021. The company raised its 2022 revenue guidance to between $1.105 billion and $1.150 billion, incorporating $20 million from the recent acquisition of In2Bones Global, subject to regulatory approval. Adjusted diluted EPS guidance is now $3.50 to $3.65.
CONMED Corporation (NYSE: CNMD) has announced a rescheduled date for its first quarter 2022 financial results due to a corporate conflict. The results will now be reported on May 4, 2022, after market close, instead of the previously scheduled April 27, 2022. A conference call will be held at 4:30 p.m. ET the same day. Updated dial-in information for the call is provided, and it will also be available via webcast. A replay will be accessible from 7:30 p.m. ET on May 4 to 11:59 p.m. ET on May 18.
CONMED Corporation (NYSE: CNMD) will announce its financial results for Q1 2022 on April 27, 2022, after market close. A conference call will follow at 4:30 p.m. ET. Investors can join the call at 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 9693807. The call will also be webcast on CONMED's website. A recording will be available from 7:30 p.m. ET on the same day until 7:30 p.m. ET on May 4, 2022.
CONMED Corporation (NYSE: CNMD) announced its Annual Meeting of Stockholders will take place virtually on May 25, 2022, at 1:30 p.m. ET. Shareholders on record as of April 5, 2022 can vote. Detailed participation instructions will be provided in the proxy statement to be filed on April 15, 2022, available on the company's website. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, scheduled for payment on April 5, 2022. Shareholders on record as of March 15, 2022 will be eligible for this dividend. This decision underscores the company's commitment to returning value to its shareholders. CONMED specializes in medical technology, providing surgical devices for various specialties, which positions it well within the healthcare sector.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q4 and full year 2021. Q4 sales reached $274.0 million, an increase of 8.4% year-over-year. Domestic revenue rose 5.0% while international sales surged 12.7%. Q4 diluted EPS stood at $0.75, down from $0.81 in 2020, yet adjusted EPS rose to $1.07 from $0.84. For 2021, total sales hit $1.01 billion, a 17.2% increase. The company anticipates 2022 revenue of $1.075 billion to $1.125 billion and adjusted EPS between $3.60 and $3.85.
CONMED Corporation (NYSE: CNMD) will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 9:00 a.m. ET. The presentation will feature Curt R. Hartman, Chair of the Board, President & CEO, and Todd W. Garner, Executive Vice President and CFO. Investors can access a live webcast through the Company’s website, with a replay available afterward. CONMED is a medical technology company providing surgical devices for minimally invasive procedures across various specialties.